A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Study Purpose

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There is an unmet medical need for effective treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease symptoms. Risankizumab is a drug being studied for the treatment for plaque psoriasis in pediatric participants. This study has 4 parts. Part 1: Participants aged 12 < 18 will receive a fixed dose of risankizumab. Part 2: Participants aged 12 < 18 will receive;

  • - Period A: Risankizumab or ustekinumab based on body weight followed by; - Period B: Risankizumab or no treatment.
  • - Period C: Re-treatment with risankizumab (if needed).
Part 3 and Part 4: Participants aged 6 < 12 will receive risankizumab based on body weight. Around 132 participants will be enrolled in approximately 30 sites worldwide. Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection. Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks. Part 2:
  • - Period A: Risankizumab or ustekinumab for 16 weeks.
  • - Period B: Risankizumab or no treatment for 36 weeks.
  • - Period C: Re-treatment with risankizumab for 16 weeks.
Follow-up call 20 weeks later for a study duration of approximately 81 weeks. Participants from each Part who meet eligibility criteria for an open-label extension (OLE) study may continue on risankizumab for 52 additional weeks. There may be a higher burden for study participants compared to standard treatment. Participants will attend monthly visits and medical assessments will check the effect of treatment through blood tests, questionnaires, and checking for side effects.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 6 Years - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Diagnosis of chronic plaque psoriasis for at least 6 months before the Baseline Visit.
  • - Stable severe or moderate to severe plaque psoriasis as defined in each study part by body surface area (BSA) psoriasis involvement and scores on the PASI and sPGA.
  • - Candidate for systemic therapy as assessed by the investigator and meet the disease activity criteria at both the Screening and Baseline Visits per the protocol.

Exclusion Criteria:

  • - Concurrent clinically significant medical conditions other than the indication being studied or any other reason that the investigator determines would interfere with the participant's participation in this study, would make the participant an unsuitable candidate to receive study drug, or would put the participant at risk by participating in the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04435600
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

AbbVie
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

AbbVie Inc.
Principal Investigator Affiliation AbbVie
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Psoriasis
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Part 1: Risankizumab Dose A

Participants age 12 to less than 18 receive fixed dose of risankizumab Dose A for 40 weeks.

Experimental: Part 2: Ustekinumab Dose A or B then Risankizumab Dose A or B

Participants age 12 to less than 18 will receive: Period A: Ustekinumab Dose A or Dose B based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Risankizumab Dose A or B based on body weight for 24 weeks.

Experimental: Part 2: Risankizumab Dose A or B

Participants age 12 to less than 18 will receive: Period A: Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4). Period B: Participants who respond to Risankizumab in Period A are re-randomized to continue Risankizumab Dose A or B based on body weight for up to 24 weeks or withdraw from treatment until flare. Period C: Participants withdrawn from treatment in Period B and experience a flare in symptoms at Week 28 or beyond are eligible for re-treatment with Risankizumab Dose A or B based on body weight for 16 weeks (at Week 0 and Week 4).

Experimental: Part 3: Risankizumab Dose A or B

Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.

Experimental: Part 4: Risankizumab Dose A or B

Participants age 6 to less than 12 will receive Risankizumab Dose A or B based on body weight for 40 weeks.

Interventions

Drug: - Risankizumab

Subcutaneous Injection

Drug: - Ustekinumab

Subcutaneous Injection

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Tien Q Nguyen MD, Inc /ID# 217733, Fountain Valley, California

Status

Recruiting

Address

Tien Q Nguyen MD, Inc /ID# 217733

Fountain Valley, California, 92708-3701

Sacramento, California

Status

Recruiting

Address

Integrative Skin Science and Research /ID# 221741

Sacramento, California, 95815-4500

Solutions Through Adv Rch /ID# 217936, Jacksonville, Florida

Status

Recruiting

Address

Solutions Through Adv Rch /ID# 217936

Jacksonville, Florida, 32256

Olympian Clinical Research /ID# 217941, Tampa, Florida

Status

Recruiting

Address

Olympian Clinical Research /ID# 217941

Tampa, Florida, 33609

Darien, Illinois

Status

Not yet recruiting

Address

University Dermatology and Vein Clinic, LLC /ID# 222778

Darien, Illinois, 60561

Arlington Dermatology /ID# 217472, Rolling Meadows, Illinois

Status

Recruiting

Address

Arlington Dermatology /ID# 217472

Rolling Meadows, Illinois, 60008

Columbus, Ohio

Status

Recruiting

Address

The Ohio State University - Columbus /ID# 217808

Columbus, Ohio, 43210

Tulsa, Oklahoma

Status

Recruiting

Address

Vital Prospects Clinical Research Institute, PC /ID# 217960

Tulsa, Oklahoma, 74136-7049

Arlington, Texas

Status

Recruiting

Address

Arlington Research Center, Inc /ID# 217471

Arlington, Texas, 76011

Kenosha, Wisconsin

Status

Not yet recruiting

Address

Clinical Investigation Specialist, Inc - Kenosha /ID# 223161

Kenosha, Wisconsin, 53144-1782

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.